Commercial Court hearing to examine the takeover offer scheduled for December 18, 2023
December 04 2023 - 1:00AM
Commercial Court hearing to examine the
takeover offer scheduled for December 18, 2023
Paris, France, December 4,
2023 – 7:00 am
(CET) – Pixium Vision SA (Euronext Growth Paris -
FR001400JX97; Mnemo: ALPIX), a bioelectronics company developing
innovative vision systems to enable patients who have lost their
sight to live more independent lives, announces that the Paris
Commercial Court will hold a hearing to examine the takeover offer
received by the court-appointed administrators and to decide on the
outcome of the Company’s reorganization proceedings on December 18,
2023.
As a reminder, only one takeover offer was
submitted before the deadline for submission of offers, which was
set to November 20, 2023 at noon. The candidate will have until
December 13, 2023 to improve its offer.
Concurrently with the decision of the Commercial
Court ruling on the takeover offer, the Court will order the
Company's judicial liquidation. In this context, the Company will
apply to Euronext for the delisting of Pixium’s shares.
The Company draws investors’ attention to the
fact that, given the current offer and the Company’s level of
indebtedness, the sale proceeds received in the event of a
favourable decision by the Commercial Court will not allow a total
or partial reimbursement of shareholders.
About Pixium Vision
Pixium Vision is creating a
world of bionic vision for those who have lost their sight,
enabling them to regain visual perception and greater autonomy.
Pixium Vision’s bionic vision systems are associated with a
surgical intervention and a rehabilitation period. Prima System
sub-retinal miniature photovoltaic wireless implant is in clinical
testing for patients who have lost their sight due to outer retinal
degeneration, initially for atrophic dry age-related macular
degeneration (dry AMD). Pixium Vision collaborates closely with
academic and research partners, including some of the most
prestigious vision research institutions in the world, such as
Stanford University in California, Institut de la Vision in Paris,
Moorfields Eye Hospital in London, Institute of Ocular Microsurgery
(IMO) in Barcelona, University hospital in Bonn, and UPMC in
Pittsburgh, PA. The Company is EN ISO 13485 certified and qualifies
as “Entreprise Innovante” by Bpifrance.
For more information:
http://www.pixium-vision.com/fr
Follow us on @PixiumVision;
www.facebook.com/pixiumvision
www.linkedin.com/company/pixium-vision
Contacts
Investor
RelationsPixium VisionOffer NonhoffChief
Financial Officerinvestors@pixium-vision.com |
Media
Relations Rose Piquante ConsultingSophie
BaumontSophie.baumont@rosepiquante-consulting.com+33 6 27 74 74
49 |
- Pixium - PR hearing examining the offer - 01.12.2023
Pixium Vision (EU:ALPIX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Pixium Vision (EU:ALPIX)
Historical Stock Chart
From Jul 2023 to Jul 2024